Exenatide Beneficial for Parkinson’s Disease (PD)

A follow-up study of patients with PD who participated in an earlier "proof of concept" clinical trial using exenatide showed that improvements persisted twelve months after discontinuing exenatide therapy. Several recent discoveries have highlighted common cellular pathways that potentially relate neurodegenerative processes with abnormal mitochondrial function and abnormal glucose metabolism. These data provide strong encouragement for the further study of this drug in patients with PD. Journal of Parkinson’s Disease May 2014